The Latest

Ending the HIV Epidemic Will Take More Than Medicine

Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.

By Stephaun E. Wallace, Ph.D.

Making Trans Women Count in HIV Vaccine Trials

"For us who focus on HIV prevention research, it is paramount that we go where the epidemic is in this country," said Michele Andrasik, Ph.D.

By Stephen Hicks

New Campaign, Toolkit Gets Providers PrEP'd for Women

New York City aims to expand PrEP and PEP access by educating more clinicians that serve women.

By Kenyon Farrow

This Week in HIV Research: Fentanyl Smooths the Path for HIV

April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Prevention and Treatment in the Real World

Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.

By Barbara Jungwirth and Myles Helfand

Drug Use May Be Increasing Syphilis Rates Among HIV-Positive Cisgender Women, Studies Show

The global increase in sexually transmitted infections was a major focus of the CROI 2019 meeting in Seattle, Washington.

By Kenyon Farrow

'Female Condom' Gets a Genderless Rebrand From FDA

After years of pressure from prevention advocates, FDA has finally given the other rubber a new name - the internal condom – and a new classification.

By Martha Kempner

Aspirin Could Help Reduce HIV Infections in Women

"We are not yet at the stage where aspirin can be recommended for preventing HIV, but the potential for another tool in our belt against a virus that has killed 35 million people (almost the population of Canada), can only be good news."

By Colin Graydon and Monika Kowatsch for The Conversation

How Does the Microbiome Impact HIV Risk and Treatment?

The vaginal, anal, and gut microbiome regions are now the focus of intense HIV-related research, with potentially wide-ranging implications stretching from prevention to patient care.

By Sony Salzman

Dapivirine Vaginal Ring for PrEP Does Not Lead to Drug Resistance

Use of the dapivirine vaginal ring for pre-exposure prophylaxis (PrEP) does not lead to resistance mutations in women who seroconvert, Urvi Parikh, Ph.D., reported at the HIV Research for Prevention 2018 conference.

By Barbara Jungwirth